Investigations and product development support for increased access to therapies.
R3 stands for Rapid Response, Effective Resolution, and Permanent Reduction.
Minerva’s R3 approach provides a comprehensive solution to all your process and quality investigation needs, avoiding the recurrence of issues while ensuring optimal outcomes.
LC3 services stands for Scientific Characterization, Insightful Comprehension, and Clear Communication.
The LC3 investigations enhance the R3 investigations or functions as a standalone service to streamline product development and improvements.
Minerva’s R3 and LC3 Approaches, when combined, create a robust framework for addressing the need of quality investigations and scientific process improvements.
through ecosystem of humans, robots, automation and knowledge.
for enhanced understanding and communication of complex procedures through job aids, enabling better decision-making, collaboration, and risk reduction.
to streamline and enhance processes in cell and gene therapy development and manufacturing by creating reports, graphics and inferences that reveal gaps, strengths and opportunities, facilitating information-based decision making.
to capture and organize data for better process understanding and decision making, resulting in optimized knowledge retention and more innovation.
to structure and convert data from systems and processes into information, fostering a culture of continuous improvement of resources, time and materials.
to identify, evaluate and mitigate risks across development and commercialization, ensuring compliance with regulatory standards and leveraging the latest industry practices.
using robotics technology to automate testing and analysis in advanced therapy manufacturing, facilitating various analytical assays such as cell counting, viability assessment, potency testing, and purity analysis for high throughput and reproducibility.
including efficient storage, retrieval and transportation of raw materials, reagents and finished products within manufacturing and testing facilities.
Advancing cell and gene therapy processes through innovative solutions and cutting-edge technologies to accelerate timeliness and improve accessibility.
